Menu

Gene Drive Limitations

In lab populations of genetically engineered mosquitoes, mutations arose that blocked the gene drive’s spread and restored female fertility.

Oct 9, 2017
Jef Akst

Anopheles gambiae mosquitoFLICKR, NIAID Researchers have eyed gene drives—selfish genetic elements that promote their own inheritance and spread—for controlling populations of disease-carrying mosquitoes. But a new study published last week (October 4) in PLOS Genetics documents a major hurdle: preventing the insects’ evolution to resist the effects of the introduced genetic element. 

Tony Nolan of Imperial College London, U.K., and colleagues designed a gene drive that targeted genes involved in egg production to successfully reduce the number of offspring that female Anopheles gambiae mosquitoes produced. The drive included a CRISPR-Cas9–based system to copy the fertility-reducing elements onto homologous chromosomes, so that the gene drive was inherited by nearly all offspring, rather than just half—resulting in its spread through the entire captive population within just four generations. But the insects soon began to evolve mutations that restored fertility and blocked the continued spread of the gene drive.

“Reducing the numbers of mosquito vectors has been the most effective tool to date for the control of malaria, so self-sustaining gene drives designed with this purpose have great potential,” Nolan says in a press release. “However gene drives are not a silver bullet and just like antibiotics can select for resistance in bacteria, gene drives can be susceptible to resistance at their target site.”

See “Using Gene Drives to Limit the Spread of Malaria” (written by Nolan and colleague)

Without gene drive, an allele will be passed from generation to generation via traditional Mendelian genetics. That is, when a heterozygous individual carrying only one copy of the allele mates with an individual lacking it, only half of their offspring will inherit the genetic segment. But in a gene drive that spreads the allele to the homologous chromosome in the germline, all progeny will receive a copy.

 

See “Infographic: Using Gene Drive to Control Malaria

Documenting mutations that convey resistance to a gene drive, as this study does, could inform the future development of more-robust technologies, the researchers say. “Our findings allow us to improve predictions on gene drive behaviour and to make concrete recommendations on how to improve future gene drive designs by decreasing the likelihood that they generate resistance,” they write in their paper.

April 2019

Will Car T Cells Smash Tumors?

New trials take the therapy beyond the blood

Marketplace

Sponsored Product Updates

Myth Busting: The Best Way to Use Pure Water in the Lab
Myth Busting: The Best Way to Use Pure Water in the Lab
Download this white paper from ELGA LabWater to learn about the role of pure water in the laboratory and the advantages of in-house water purification!
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu Corporation announces the release of the Nexera Ultra High-Performance Liquid Chromatograph series, incorporating artificial intelligence as Analytical Intelligence, allowing systems to detect and resolve issues automatically. The Nexera series makes lab management simple by integrating IoT and device networking, enabling users to easily review instrument status, optimize resource allocation, and achieve higher throughput.
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
Increasing accuracy and reducing cost barriers, IDT’s innovative system delivers simple and cost-effective amplicon sequencing
Bio-Rad Introduces Isotype-Specific Secondary Antibodies
Bio-Rad Introduces Isotype-Specific Secondary Antibodies
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of its isotype-specific secondary antibodies. This new range of recombinant monoclonal antibodies, directed against the three main mouse isotypes: IgG1, IgG2a, and IgG2b, offer improved signal detection and specificity in imaging, ELISA, flow cytometry, and western blotting.